Mason Marks

Mason Marks is the Florida Bar Health Law Section Professor at Florida State University College of Law. He is the senior fellow and project lead of the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and an affiliated fellow at the Information Society Project (ISP) at Yale Law School. Marks was previously a fellow-in-residence at the Edmond J. Safra Center for Ethics at Harvard University, a research scholar at the Information Law Institute at NYU Law School, and a visiting fellow at Yale Law School's ISP. 

Marks's academic research focuses on health technology, FDA regulation, and constitutional law. He is particularly interested in state and federal controlled substance regulation, health privacy, and the application of artificial intelligence to medical decision making. His academic writing has been published or is forthcoming in the Duke Law Journal, the Harvard Law Review Forum, the Boston University Law Review, UC Irvine Law Review, the UC Davis Law Review, the Administrative Law Review, the Yale Journal of Law and Technology, the NYU Journal of Legislation and Public Policy, and books by Cambridge University Press. 

In addition to legal scholarship, Marks writes about law and technology for publications such as The Washington Post¹, the Los Angeles Times², the Guardian³, the Seattle Times⁴, Slate⁵, WIRED⁶, Vice News⁷, Gizmodo⁸, STAT News⁹, and the Houston Chronicle¹⁰. His legal commentary has been featured by The New York Times¹¹, The Wall Street Journal¹², The Washington Post, ABC News¹³, Fox News¹⁴, Bloomberg News¹⁵, the Economist¹⁶, the Telegraph, Radio Boston, German Public Radio, and NPR's All Things Considered.

At Florida State University, Marks teaches Constitutional Law, Drug Law, and Legislation and Regulation. An expert on the fast-emerging psychedelics industry, he has presented his research at the Food and Drug Administration, the Department of Health and Human Services, the National Institutes of Health, and the National Academies of Sciences, Engineering, and Medicine. 

Marks has advised city, state, and federal officials on the rapidly evolving regulatory landscape regarding psychedelics. He served as a founding member of the Oregon Psilocybin Advisory Board, where he chaired the Licensing Subcommittee, and drafted psychedelics legislation adopted by the Washington State Legislature and the Seattle City Council. 

Social Media Links

Twitter: https://twitter.com/MasonMarksMD¹⁷ (@MasonMarksMD)

LinkedIn: https://www.linkedin.com/in/masonmarks/¹⁸